← Back to Search

Antiandrogen

Ribociclib + Bicalutamide for Breast Cancer

Phase 1 & 2
Recruiting
Led By Kari Wisinski, MD
Research Sponsored by Ruth O'Regan, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to swallow bicalutamide and ribociclib capsules/tablets
Age ≥ 18 years at the time of consent
Must not have
Received radiotherapy <14 days prior to registration and not recovered to grade 1 or better from related side effects
Had major surgery within 14 days prior to registration or not recovered from major side effects of the surgery
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Summary

This trial tests the combination of ribociclib and bicalutamide in patients with advanced AR+ triple-negative breast cancer. The drugs aim to stop cancer growth by blocking hormones and proteins that the cancer cells need to multiply.

Who is the study for?
This trial is for adults with advanced AR+ triple-negative breast cancer who haven't had certain treatments, have no active brain metastases, and whose major organs function well. They must not be pregnant or breastfeeding, agree to use contraception, and can swallow pills. Excluded are those with recent heart issues, strokes, uncontrolled conditions that could affect safety or compliance, known HIV infection or other active cancers needing treatment.
What is being tested?
The study tests ribociclib in combination with bicalutamide on patients with a specific type of breast cancer (AR+ TNBC). It's an open-label phase II trial without randomization or blinding. Participants will receive both drugs to see how effective this combo is against their cancer.
What are the potential side effects?
Potential side effects include nausea, fatigue, low blood counts leading to increased infection risk or bleeding problems; liver issues; potential heart rhythm problems; allergic reactions; and possible interactions with other medications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can swallow pills.
Select...
I am 18 years old or older.
Select...
My breast cancer is triple-negative and cannot be surgically removed, but tests show it is AR positive.
Select...
I do not have cancer that has spread to my brain or spinal cord.
Select...
My heart's electrical activity is normal, with a safe QT interval and resting rate.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I had radiotherapy less than 2 weeks ago and still have side effects.
Select...
I have not had major surgery or recovered from its major side effects within the last 14 days.
Select...
I have a digestive condition that affects how my body absorbs medication.
Select...
I have been diagnosed with HIV.
Select...
I have Long QT syndrome or a family history of sudden death.
Select...
I am taking medication that affects my heart's rhythm and cannot stop.
Select...
I have cirrhosis with a moderate to severe liver function impairment.
Select...
I have severe heart failure or my heart's pumping ability is reduced (LVEF <50%).
Select...
I haven't had serious heart rhythm problems in the last year.
Select...
I am currently taking warfarin or a similar blood thinner.
Select...
I have another cancer that is growing and needs treatment.
Select...
I do not have any serious wounds, ulcers, or unhealed bone fractures.
Select...
I have had a heart attack or other heart issues in the last 6 months.
Select...
I have previously been treated with hormone therapies for cancer.
Select...
I haven't taken any experimental drugs recently.
Select...
I am currently on medication for an infection.
Select...
I am not taking strong drugs affecting liver enzymes that can't be stopped a week before starting the study drug.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Phase I: Maximum Tolerated Dose
Phase II: Clinical benefit rate (CBR) of treatment combination
Secondary study objectives
Phase I: Assess Safety and Tolerability By summarizing counts and percentages grade 3-5 adverse events (NCI CTCAE Version 4)
Phase I: Duration of Response
Phase I: Objective Response Rate (ORR)
+6 more

Side effects data

From 2020 Phase 3 trial • 502 Patients • NCT03096847
46%
NEUTROPENIA
43%
NAUSEA
38%
FATIGUE
33%
ALOPECIA
25%
NASOPHARYNGITIS
20%
LEUKOPENIA
20%
DIARRHOEA
20%
ASPARTATE AMINOTRANSFERASE INCREASED
19%
ARTHRALGIA
19%
ALANINE AMINOTRANSFERASE INCREASED
18%
CONSTIPATION
18%
ANAEMIA
17%
HEADACHE
17%
VOMITING
15%
NEUTROPHIL COUNT DECREASED
15%
STOMATITIS
14%
INSOMNIA
13%
PAIN IN EXTREMITY
13%
BACK PAIN
13%
DYSPNOEA
12%
HOT FLUSH
11%
RASH
11%
THROMBOCYTOPENIA
11%
OEDEMA PERIPHERAL
11%
DECREASED APPETITE
10%
URINARY TRACT INFECTION
10%
WHITE BLOOD CELL COUNT DECREASED
10%
COUGH
10%
PRURITUS
8%
ELECTROCARDIOGRAM QT PROLONGED
8%
DYSPEPSIA
8%
VERTIGO
8%
MUSCULOSKELETAL PAIN
8%
DRY SKIN
8%
GAMMA-GLUTAMYLTRANSFERASE INCREASED
6%
LACRIMATION INCREASED
6%
ABDOMINAL PAIN UPPER
6%
WEIGHT DECREASED
6%
ABDOMINAL PAIN
6%
PYREXIA
6%
BLOOD CREATININE INCREASED
6%
BONE PAIN
6%
DRY MOUTH
6%
ERYTHEMA
5%
DRY EYE
5%
DIZZINESS
4%
HYPERTENSION
4%
SLEEP DISORDER
4%
MYALGIA
4%
CYSTITIS
4%
DYSGEUSIA
4%
DEPRESSION
3%
GENERAL PHYSICAL HEALTH DETERIORATION
3%
BRONCHITIS
3%
MUSCULOSKELETAL CHEST PAIN
3%
POLYNEUROPATHY
2%
SEASONAL ALLERGY
2%
PLEURAL EFFUSION
2%
HYPOCALCAEMIA
1%
SKIN ULCER
1%
OROPHARYNGEAL PAIN
1%
URETEROLITHIASIS
1%
ARTHROPOD BITE
1%
GASTROINTESTINAL INFECTION
1%
INFLUENZA
1%
DEVICE RELATED INFECTION
1%
METASTASES TO SPINE
1%
CHEST PAIN
1%
CYSTITIS ESCHERICHIA
1%
SEPSIS
1%
INCISIONAL HERNIA
1%
COLON CANCER
1%
METASTASES TO BONE
1%
PULMONARY EMBOLISM
1%
ATRIAL FIBRILLATION
1%
ANAL HAEMORRHAGE
1%
HELICOBACTER GASTRITIS
1%
TUMOUR LYSIS SYNDROME
1%
TUMOUR PAIN
1%
WEIGHT INCREASED
1%
PANIC ATTACK
1%
FLANK PAIN
1%
SPINAL PAIN
1%
FEBRILE NEUTROPENIA
1%
CARDIAC FAILURE
1%
ILEUS
1%
INTESTINAL STRANGULATION
1%
COMPLICATION OF DEVICE INSERTION
1%
IMPAIRED HEALING
1%
PAIN
1%
HEPATIC CIRRHOSIS
1%
ABSCESS JAW
1%
APPENDICITIS
1%
MASTITIS
1%
PNEUMONIA
1%
HIP FRACTURE
1%
JAW FRACTURE
1%
RADIUS FRACTURE
1%
BLOOD BILIRUBIN INCREASED
1%
HYPERCALCAEMIA
1%
HYPERKALAEMIA
1%
DEVICE LOOSENING
1%
RENAL FAILURE
1%
RENAL IMPAIRMENT
1%
CIRCULATORY COLLAPSE
1%
TOOTHACHE
1%
BLOOD LACTATE DEHYDROGENASE INCREASED
1%
HYPOAESTHESIA
1%
HYPERFIBRINOLYSIS
1%
DRUG-INDUCED LIVER INJURY
1%
ABDOMINAL PAIN LOWER
1%
DEHYDRATION
1%
OSTEITIS
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ribociclib + Letrozole Cohort B2
Ribociclib + Letrozole Cohort A
Ribociclib + Letrozole Cohort B1
Total
Ribociclib + Letrozole Cohort B

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm A - Phase IExperimental Treatment2 Interventions
Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle. Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle. Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle. Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 25 patients.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bicalutamide
2003
Completed Phase 3
~6210
ribociclib
2023
Completed Phase 3
~630

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Ribociclib is a CDK4/6 inhibitor that blocks proteins essential for cell cycle progression, thereby halting cancer cell proliferation. Bicalutamide is an androgen receptor antagonist that prevents androgens from stimulating cancer cell growth. These mechanisms are crucial for patients with androgen receptor-positive breast cancer, as they target specific pathways involved in cancer growth, leading to more personalized and effective treatments.

Find a Location

Who is running the clinical trial?

Ruth O'Regan, M.D.Lead Sponsor
University of Wisconsin, MadisonOTHER
1,217 Previous Clinical Trials
3,163,319 Total Patients Enrolled
36 Trials studying Breast Cancer
38,481 Patients Enrolled for Breast Cancer
Kari WisinskiLead Sponsor
2 Previous Clinical Trials
81 Total Patients Enrolled

Media Library

Bicalutamide (Antiandrogen) Clinical Trial Eligibility Overview. Trial Name: NCT03090165 — Phase 1 & 2
Breast Cancer Research Study Groups: Arm A - Phase I
Breast Cancer Clinical Trial 2023: Bicalutamide Highlights & Side Effects. Trial Name: NCT03090165 — Phase 1 & 2
Bicalutamide (Antiandrogen) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03090165 — Phase 1 & 2
~5 spots leftby Oct 2025